KRAS and colorectal carcinoma: These findings reveal a novel mechanism of acquired drug resistance in KRAS-mutant CRC, wherein Jag1-ICD functions as a novel nuclear effector downstream of the KRAS signaling pathway [21,22] (Figure 3).